The estimated Net Worth of Kevin M Klemz is at least $4.57 Million dollars as of 19 August 2024. Kevin Klemz owns over 2,268 units of Silk Road Medical Inc stock worth over $4,438,104 and over the last 9 years Kevin sold SILK stock worth over $135,286.
Kevin has made over 3 trades of the Silk Road Medical Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Kevin sold 2,268 units of SILK stock worth $61,463 on 19 August 2024.
The largest trade Kevin's ever made was selling 2,497 units of Silk Road Medical Inc stock on 1 March 2024 worth over $42,873. On average, Kevin trades about 1,051 units every 61 days since 2015. As of 19 August 2024 Kevin still owns at least 162,926 units of Silk Road Medical Inc stock.
You can see the complete history of Kevin Klemz stock trades at the bottom of the page.
Kevin's mailing address filed with the SEC is 1213 INNSBRUCK DRIVE, , SUNNYVALE, CA, 94089.
Over the last 6 years, insiders at Silk Road Medical Inc have traded over $925,682,871 worth of Silk Road Medical Inc stock and bought 14,200 units worth $302,033 . The most active insiders traders include X Finance, L.P.Wpx Gp, L.P...., Pincus & Co.Kaye Charles R ..., and Pincus & Co.Warburg Pincus .... On average, Silk Road Medical Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,280,712. The most recent stock trade was executed by Kevin M Klemz on 19 August 2024, trading 2,268 units of SILK stock currently worth $61,463.
silk road medical, inc. is a privately held company located in sunnyvale, california, dedicated to preventing the devastating burden of stroke through surgical innovation. the company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. by innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. for more information on the company, visit our website at http://silkroadmed.com/. the transcarotid artery revascularization (tcar) procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. th
Silk Road Medical Inc executives and other stock owners filed with the SEC include: